Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Staphylococcal enterotoxin B (SEB) is a bacterial protein toxin and superantigen produced by Staphylococcus aureus. SEB functions as a potent virulence factor responsible for staphylococcal food poisoning and is a leading cause of toxic shock syndrome. It achieves its effects by simultaneously binding to major histocompatibility complex (MHC) class II molecules on antigen-presenting cells and T-cell receptors (TCR) on T cells, specifically cross-linking them in a manner independent of antigen specificity and resulting in massive, polyclonal T-cell activation. This leads to an uncontrolled release of pro-inflammatory cytokines (a "cytokine storm"), which can cause severe inflammation, shock, and potentially death[1][3][6]. Structurally, SEB is a stable protein with a distinctive two-domain fold and is capable of withstanding high temperatures, remaining active even after boiling for short periods[6][9]. SEB does not possess enzymatic activity but exerts its toxicological effects via immune modulation as a superantigen. Due to its potency, stability, and ease of production, SEB is classified as a potential biological warfare agent and remains a target for the development of inhibitory therapeutics and diagnostic methods[9]. Experimental drug candidates include peptides that can interfere with SEB binding to immune receptors, reducing pathological immune activation[7].
Superantigen cross-links MHC class II molecules and T-cell receptors independent of antigen, massively activating T cells; Induces release of pro-inflammatory cytokines (cytokine storm); Some experimental peptides block SEB-TCR or SEB-CD28 binding to mitigate cytokine storm[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Staphylococcal enterotoxin B (SEB).